

Clinical manifestations of Dermatophytoses and its treatment: A Review

ABSTRACT

Dermatophytes can invade the keratinized tissue and cause one of the most common fungal infections, dermatophytoses. Dermatophytoses are present worldwide and it is most common in warm climates. It is caused by dermatophytes that belong to the genera *Trichophyton*, *Epidermophyton* and *Microsporum*. The clinical manifestation and clinical signs of these infections vary according to the infected body part and the specific dermatophytic species. According to the parts of the body that is affected, clinical manifestations of the dermatophytoses are categorized, such as tinea capitis (scalp), tinea barbae (beard area), tinea corporis (skin other than the bearded area, scalp, hands or feet), tinea cruris (groin and perineal areas), tinea pedis (feet), tinea manuum (hands), and tinea unguium (nails). *Trichophyton rubrum*, *T. mentagrophytes*, *T. tonsurans*, *Epidermophyton floccosum* and *Microsporum canis* are the main etiological species for dermatophytoses in all over the world. In this review we discuss about the clinical manifestations of dermatophytoses, etiological agents and their treatment by using oral and topical antifungals.

KEY-WORDS- Dermatophytoses, clinical manifestation, anti-fungal, treatment etc.

INTRODUCTION

The dermatophytes are a collection of keratinophilic fungi that share a great deal with similarity in their morphology and genetic characteristics [1,2]. They are able to invade the keratinized tissue of animals and humans, which can cause fungal infection known as dermatophytoses [3]. *Trichophyton*, *Epidermophyton*, *Microsporum*, *Arthroderma*, *Nannizzia*, *Paraphyton* and *Lophophyton* are the names of genera given to the different types of dermatophytes that are categorized under the new system of classification. [4]. In the order Onygenales, the dermatophytes are Ascomycetes that have septate hyphae and they are most closely connected to *Coccidioides immitis* [5,6].

The World Health Organization estimates that dermatophytoses impact 20 to 25 percent of the world's population [7]. In addition, research has shown that the reactions of different species

of dermatophytes to antifungal medications are not the same [8]. Fungi that have successfully colonized in the skin will eventually reproduce and spread throughout the superficial layers of skin and cause fungal cutaneous infections.

The broad spectrum of fungal cutaneous infections are caused by organisms that are anthropophilic. Transmission can take place either through direct contact or through exposure to cells that have been desquamated. People who have a compromised cell-mediated immune system are more susceptible to acquire an infection directly through rupture in to the epidermis.

TYPES OF DERMATOPHYTIC FUNGI

Fungi that live on the skin are linked to a number of the world's most prevalent diseases, including dandruff and atopic dermatitis/eczema. The natural epidemiological perspective recognises three classes of dermatophytes based on their habitat, which are anthropophilic, zoophilic and geophilic. Anthropophilic dermatophytes are found in humans and zoophilic dermatophytes are found in various animal hosts while geophilic dermatophytes are found in different soil texture. Dermatophytes can be passed from one individual to another without any intermediary (anthropophilic organisms). Other geophilic dermatophytes are found in the soil and can be passed on to humans from there, while still others can be transmitted on to humans from animal hosts (zoophilic organisms) [9]. Transmission of dermatophytes can also take place in an indirect manner through fomites. (e.g., upholstery, hairbrushes, hats). The following table provides an overview of the most dermatophytic species and the habitat in which they are present [10].

Table No. 1: Source of most common dermatophytic species causing dermatophytoses in animals and humans on the basis of their habitats.

Source for isolation	Affected organism	Isolated species	Clinical type of dermatophytoses	Reference
Anthropophilic	Human	<i>Trichophyton rubrum</i>	Tinea pedis, Onchomycosis, tinea cruris, tinea faciei, tinea corporis, tinea manuum, tinea barbae	[11,12,13,14,15,16,17]
	Human	<i>T. tonsurans</i>	Tinea capitis, tinea corporis, tinea faciei	[15,14,16,17]
	Human	<i>Epidermophyton floccosum</i>	Tinea cruris	[17]

	Human	<i>T. digitale</i>	Tinea pedis	[18,17]
	Human	<i>T. digitale</i>	Tinea capitis favosa	[18,17]
Zoophilic	Cats	<i>Microsporumcanis</i>	Ringworm	[19,20,17]
	Voiles, bats	<i>Arthrodermapersicolor</i>	Ringworm	[21,17]
	Pigs	<i>M. nanum</i>	Ringworm	[17]
	Horses	<i>T. equinum</i>	Ringworm	[22,17]
	Mice, guinea pigs	<i>T. mentagrophytes</i>	Ringworm	[20,17]
	Cattle	<i>T. verrucosum</i>	Ringworm	[23,24,17]
	Monkey, Chicken, dogs	<i>T. simmi</i>	Ringworm, Tinea capitis (humans)	[25]
Geophilic	Animal and human	<i>M. gypseum</i>	Ringworm, tinea capitis/tinea corporis (humans)	[19,26,27,17]

MECHANISM OF ACTION OF INVADING DERMATOPHYTIC FUNGI

Dermatophytes are aerobic fungi that secrete proteases enzyme that digest keratin protein, which enables them to invade, colonize and infect the stratum corneum of the epidermis as well as the hair shaft and the nail [28,29]. Dermatophytes are unable to infiltrate in the deeper layers of tissue or organs in the healthy immune-competent host, the infection is typically limited to the cornified layers of the skin and is generally confined to the surface. The infection caused by dermatophytes is also known as "Ringworm" in popular parlance [30,31].





CLINICAL TYPES OF DERMATOPHYTOSES

The dermatophytes are responsible for illness in humans and animals including domestic animals. It is often that dermatophyte infections are the most common human infection in all over the world (not just the most common fungal infection). Infections caused by

dermatophytes are accountable for the expenditure of at least half a billion dollars in health care [32]. Table shows most common dermatophytic infections and their locations in body.

Table No. 2: Clinical Manifestations of Dermatophytoses/Tinea.

Tinea infection	Affected Body Part	Photograph
Tinea capitis	Scalp	
Tinea corporis	Abdomen	
Tinea barbae	Beard	
Tinea faciei	Face	

Tinea manuum	Hands	
Tinea cruris	Groin	
Tinea pedis	Feet	
Tinea unguium	Nails	

Some of the most common clinical manifestations of dermatophytoses-

TINEA CAPITIS

Tinea capitis is an infection that affects both the scalp and the shafts of the hair. Tinea capitis is characterised by baldness that is either well-defined or not well-defined at all, as well as scaling. The condition known as "black dot" alopecia is caused when enlarged hairs break off just a few millimetres from the scalp. This type of dermatophytoses can also lead to a cell-mediated immune reaction known as a "kerion" which is a mass on the scalp that is sterile, inflammatory and full of muck. Tinea capitis is the most prevalent type of dermatophytoses occurs in children below 12 years of age who had at least three of the following clinical features: scaling on the scalp, itching on the scalp, occipital adenopathy, and diffuse, patchy or discrete alopecia [33,34,35]. Tinea capitis most often caused by any of the dermatophytic species belonging to two genera: *Trichophyton* and *Microsporum*[36,37]. The main causative agents are *T. tonsurans* and *M. canis*[38,39]. Transmission of this infection can take place through contaminated hats, brushes, pillow and other inanimate objects. Poor sanitation and overcrowding are two factors that contribute to the spread of the disease. Affected hair can continue to harbour viable organisms for longer than one year after they have been released.

TINEA CORPORIS

Tinea corporis more commonly known as ringworm, manifests itself as a single or numerous annular, scaly lesions on the trunk, extremities and face. These lesions typically have a central clearing, a slightly elevated, reddened border and sharp margination (an abrupt transition from infected to uninfected skin). There is a possibility of pustules or follicular papules forming along the margin of the disease. The level of itching varies [40]. Tinea corporis is most commonly caused by dermatophytes belonging to one of the three genera, namely *Trichophyton*, *Microsporum* and *Epidermophyton*[41]. This type of dermatophytoses is most often caused by *T. rubrum*, *T. tonsurans* and *M. canis*[42]. *T. rubrum* is the most common cause of dermatophytoses around worldwide and it is the most common cause of tinea corporis[43].

TINEA BARBAE

Tinea barbae affects both the skin and the coarse hair in the region of the beard and moustache. Adult males are more likely to contract this dermatophytic condition. The most common causative agents for tinea barbae are *T. verrucosum* and *T. mentagrophytes*. These pathogens are contracted through occupational exposure to animals infected with zoophilic

dermatophytes. Farm employees are the most likely to become infected because this type of infection is typically caused by a zoophilic organism [44,45].

TINEA FACIEI

Tinea faciei typically appears on the areas of the face that are uncovered by facial hair. It is usually seen in children and women [46]. The patient may report symptoms of itching and burning, both of which are known to become more severe when exposed to sunshine. There are a few crimson spots that are circular or annular in shape. The red areas, on the other hand, may be difficult to distinguish, particularly on skin with a dark pigmentation, and lesions may have very little or no scaling and may not have raised borders. Most common pathogens of tinea faciei are *T. tonsurans*, *T. verrucosum*, *T. mentagrophytes*, *M. canis* and *T. rubrum* [47]. This dermatophytosis is sometimes referred to as "tinea incognito" due to the fact that it has a relatively inconspicuous appearance [48].

TINEA MANUUM

Tinea manuum is a fungal condition that can affect palm, dorsum or interdigital folds of one or both hands. Adolescent and adult males are the more frequently affected [49]. In this type the palms become diffusely dry, scaly and erythematous. The most common agent for this dermatophytosis worldwide is *T. rubrum* [50]. *T. mentagrophytes*, *T. interdigitale* and *E. floccosum* are the other most etiological agents for tinea manuum [51,52].

TINEA CRURIS

Tinea cruris, also known as "jock itch" caused by dermatophytes that affects the groin area. Tinea cruris is a condition that primarily affects the proximal and medial thighs, but it can also spread to the buttocks and midsection. Patients who have this type of dermatophytosis frequently report symptoms including itchiness and burning. On a background of red, scaling lesions with raised borders, pustules and vesicles are present at the active edge of the infected region, along with maceration. These lesions are present in addition to the maceration [53,54]. The most important causative dermatophytic agents of tinea cruris are *T. rubrum*, *E. floccosum*, *T. interdigitale*, *T. mentagrophytes* and *T. verrucosum* in Iran and other countries [55,52,56]. This dermatophytosis is more prevalent in males. A suffocating environment, such as that created by damp clothing or clothing that fits too snugly, is ideal condition for the spread of infection.

TINEA PEDIS

Tinea pedis or athlete's foot is an infection of the feet including the soles, interdigital clefts and nails. Fissuring, maceration and scaling in the interdigital spaces of the fourth and fifth digits are the distinguishing features of this condition. Patients suffering from this condition often describe feeling like they have an itchy or burning rash. Mostly tinea pedis is caused by *T. rubrum*, *T. interdigitale* and *E. floccosum* [57,58,59]. There are a number of risk factors for acquiring these infections including residing in hot, humid environments, wearing occlusive footwear for prolonged periods of time, excessive sweating, and exposure of the skin to moisture for extended periods [60]. In the general, there has typically been a higher frequency of tinea pedis in males compared to females especially men aged between 20 and 40 years [61,62,63].

TINEA UNGUIUM

Tinea unguium or onychomycosis is an infection of the nails. The risk of this type of infection is higher in males compared to females and also increased with the age [64]. Older age, trauma, diabetes, immunosuppression and a history of tinea pedis (athlete's foot) or nail psoriasis are all the predisposing factors for tinea unguium [65]. Exposure to humid environments, unventilated footwear and traveling jobs, handwashing or communal showers facilities increase the risk of developing onychomycosis [66]. Common causative agents include *T. rubrum*, *T. interdigitale*, *E. floccosum* and *T. tonsurans* is commonly associated in infection of children [67,65].

DIAGNOSIS OF DERMATOPHYTOSES

According to Barry and Hainer dermatophytic infections can be readily diagnosed based on the history, physical examination and potassium hydroxide (KOH) microscopy [51]. Diagnosis occasionally requires Wood's lamp examination and fungal culture or histologic examination. Molecular sequencing is the new approach of diagnosis.

TREATMENT OF DERMATOPHYTOSES

Dermatophytic infections can be treated with antifungal medications that are either taken orally or applied topically or with a combination of the two [68]. All of these strategies are

targeted at destroying the fungal cell wall in order to stop the infection mechanism that the fungus uses and to kill the cells. It is standard practise to consider topical antifungals to be the first-line treatment for dermatomycoses. The technique of administration that topical antifungals use gives them the advantage of curing skin diseases by their direct application at the site of infection, making them more effective than systemic treatments, which are typically used to treat fungal infections [69]. Dermatophytoses that can be treated with both first- and second-line topical antifungal drugs, depending on the severity of the infection [70,71].

Table No. 3: Oral and topical anti-dermatophytic agents.

S.No	Antifungal agent	Clinical manifestations of dermatophytoses	Duration of tretment	Referenc es
1	Griseofulvin	Tinea corporis Tinea pedis Tinea cruris Tinea barbae	6-8 weeks	[72]
2	Clotrimazole	Tinea corporis Tinea cruris Tinea pedis	4-6 weeks	[73]
3	Terbinafine	Tinea pedis	4 weeks	[74]
		Tinea unguium	12 weeks	
		Tinea manuum	2-4 weeks	[75]
		Tinea barbae	4 weeks	[55]

		Tinea faciei	2 weeks	[76]
		Tinea capitis	4-6 weeks	[77]
4	Butenafine (1%)	Tinea corporis Tinea cruris Tinea pedis	2-4 weeks	[72]
5	Econazole nitrate (1%)	Tinea pedis	2 weeks	[78]
6	Setacozazole (2%)	Tinea corporis Tinea cruris	4 weeks	[79,80]
7	Amorofine (0.25%)	Tinea corporis	4 weeks	[81]
8	Effinaconazole (10%)	Tinea pedis	12 months	[82]

		Tinea unguium	12months	[83]
9	Amphotericin B (0.1%)	Tinea corporis Tinea cruris	4 weeks	[84]
10	Eberconazole (1%)	Tinea corporis Tinea cruris Tinea pedis	2-4 weeks	[73]
11	Naftifine (2%)	Tinea cruris	2 weeks	[85]
12	Luliconazole (1%)	Tinea corporis	1 week	[86]
		Tinea cruris	1 week	
		Tinea pedis	2weeks	

Allopathic treatment time-duration is long, expensive and not in approach of every class of the community. These chemical drugs may have various side effects such as headache, vomiting, pain, rashes, anaemia, decreased renal functions and jaundice etc. So, there is need for effective and safe antifungal treatments. In order to this, a wide variety of plant products, including flavonoids, alkaloids, saponins, oils and phytosterols are currently undergoing clinical testing as potential treatments for dermatophytic infections [87]. The ability of essential oil of plants to prevent and treat fungal infections is due to the presence of phytochemical substances. There are numerous ways to assess the essential oils in vitro antidermatophytic activity. The most common tests are the agar-based disc diffusion, broth dilution and vapour phase tests. Despite the fact that essential oils extracted from plants is widely used by humans and that there is strong evidence from recent research that they may be complimentary or alternative options for preventing and treating dermatophytoses [88].

CONCLUSION AND FUTURE PERSPECTIVE

From the present review of dermatophytic infections, it can be concluded that such kind of fungal infections might be painful and lethal if untreated. Dermatophytoses may become more prevalent under certain circumstances, including crowded living conditions, wearing tight or suffocating clothing, heightened urban living, low socio-economic status, close contact with animals and inadequate personal hygiene. The contagious nature of dermatophytic infections facilitates easy transmission to healthy individuals, with a high likelihood of spreading from animals to humans. It is noteworthy that these fungi can also spread within the same individual's body, migrating from one location to another due to their high level of contagiousness. Clinic-practitioner and researchers face significant challenges in treating dermatophytoses or tinea. These include the rising occurrence and evolving identification of dermatophytes, prolonged treatment durations, a restricted array of antifungal agents, numerous side effects associated with available medications and the emergence of drug resistance. Treatment of dermatophytic infections is possible using plant-based products and antifungal drugs. However, identification of specific compounds

responsible for antifungal potential is required to enhance plant-based therapy of dermatophytic infections.

ACKNOWLEDGEMENTS

This study was financially supported by UGC-CSIR, NEW DELHI. We are grateful for the laboratory and other facilities provided by the Head of the Botany Department at the University of Rajasthan in Jaipur.

COMPETING INTERESTS

The authors of this review paper have disclosed no conflicts of interest.

REFERENCES

1. Dabas Y, Xess I, Singh G, Pandey M, Meena S. Molecular identification and antifungal susceptibility patterns of clinical dermatophytes following CLSI and EUCAST guidelines. *Journal of Fungi*. 2017; 3(2):17.
2. Salehi Z, Shams-Ghahfarokhi M, Razzaghi-Abyaneh M. Molecular epidemiology, genetic diversity, and antifungal susceptibility of major pathogenic dermatophytes isolated from human dermatophytosis. *Frontiers in Microbiology*, 2012; 12, 643509.
3. Zareshahrabadi Z, Totonchi A, Rezaei-Matehkolaei A, Ilkit M, Ghahartars M, Arastehfar A, Motamedi M, Nouraei H, Sharifi Lari M, Mohammadi T, Zomorodian K. Molecular identification and antifungal susceptibility among clinical isolates of dermatophytes in Shiraz, Iran (2017–2019). *Mycoses*. 2021; 64(4):385-93.
4. De Hoog GS, Dukik K, Monod M, Packeu A, Stubbe D, Hendrickx M, Kupsch C, Stielow JB, Freeke J, Göker M, Rezaei-Matehkolaei A. Toward a novel multilocus phylogenetic taxonomy for the dermatophytes. *Mycopathologia*. 2017; 182:5-31.
5. Kwon-Chung, KJ, Bennett, JE. *Medical mycology*. Lea & Febiger. 1992, Philadelphia
6. Gräser Y, Scott J, Summerbell R. The new species concept in dermatophytes—a polyphasic approach. *Mycopathologia*. 2008; 166:239-56.
7. Ebert A, Monod M, Salamin K, Burmester A, Uhrlaß S, Wiegand C, Hipler UC, Krüger C, Koch D, Wittig F, Verma SB. Alarming India-wide phenomenon of antifungal resistance in dermatophytes: a multicentre study. *Mycoses*. 2020;63(7):717-28.

8. Bhatia VK, Sharma PC. Determination of minimum inhibitory concentrations of itraconazole, terbinafine and ketoconazole against dermatophyte species by broth microdilution method. *Indian journal of medical microbiology*. 2015; 33(4):533-7.
9. Fratti M, Bontems O, Salamin K, Guenova E, Monod M. Survey on dermatophytes isolated from animals in Switzerland in the context of the prevention of zoonotic dermatophytosis. *Journal of Fungi*. 2023; 14;9(2):253.
10. Kaur N, Bains A, Kaushik R, Dhull SB, Melinda F, Chawla P. A review on antifungal efficiency of plant extracts entrenched polysaccharide-based nanohydrogels. *Nutrients*. 2021; 15;13(6):2055.
11. Weitzman I, Summerbell RC. The dermatophytes. *Clin Microbiol Rev*. 1995; 8:240-59.
12. Seebacher C, Bouchara JP, Mignon B. Updates on the epidemiology of dermatophyte infections. *Mycopathologia*. 2008; 166:335-52.
13. Belhadjali H, Aounallah A, Youssef M, Gorcii M, Babba H, Zili J. Tinea faciei, underrecognized because clinically misleading. 14 cases. *Presse Medicale (Paris, France: 1983)*. 2009; 12;38(9):1230-4.
14. Achterman RR, Smith AR, Oliver BG, White TC. Sequenced dermatophyte strains: growth rate, conidiation, drug susceptibilities, and virulence in an invertebrate model. *Fungal genetics and biology*. 2011; 1;48(3):335-41.
15. White TC, Findley K, Dawson TL, Scheynius A, Boekhout T, Cuomo CA, Xu J, Saunders CW. Fungi on the skin: dermatophytes and *Malassezia*. *Cold spring harbor perspectives in medicine*. 2014;1;4(8):a019802.
16. Leung AK, Lam JM, Leong KF, Hon KL. Tinea corporis: an updated review. *Drugs in context*. 2020;9.
17. Moskaluk AE, VandeWoude S. Current topics in dermatophyte classification and clinical diagnosis. *Pathogens*. 2022; 23;11(9):957.
18. Li H, Wu S, Mao L, Lei G, Zhang L, Lu A, An L, Yang G, Abliz P, Meng G. Human pathogenic fungus *Trichophyton schoenleinii* activates the NLRP3 inflammasome. *Protein & cell*. 2013 ;4(7):529-38.
19. Moriello KA, Coyner K, Paterson S, Mignon B. Diagnosis and treatment of dermatophytosis in dogs and cats. *Clinical Consensus Guidelines of the World Association for Veterinary Dermatology*. *Veterinary dermatology*. 2017; 28(3):266-e68.

20. Pier AC, Smith JM, Alexiou H, Ellis DH, Lund A, Pritchard RC. Animal ringworm—its aetiology, public health significance and control. *Journal of Medical and Veterinary Mycology*. 1994; 1;32(sup1):133-50.
21. Krzyściak P, Al-Hatmi AM, Ahmed SA, Macura AB. Rare zoonotic infection with *Microsporumpersicolor* with literature review. *Mycoses*. 2015; 58(9):511-5.
22. Veraldi S, Genovese G, Peano A. Tinea corporis caused by *Trichophyton equinum* in a rider and review of the literature. *Infection*. 2018; 46:135-137.
23. Moretti A, Boncio L, Pasquali P, Fioretti DP. Epidemiological aspects of dermatophyte infections in horses and cattle. *Journal of Veterinary Medicine, Series B*. 1998; 12;45(1-10):205-8.
24. Chermette R, Ferreiro L, Guillot J. Dermatophytoses in animals. *Mycopathologia*. 2008; 166:385-405.
25. Gugnani HC, Thammayya A. Epidemiology of infections due to zoophilic dermatophyte *trichophyton simii*, an update. *Research in Veterinary Science and Medicine*. 2021; 16;1.
26. García-Agudo L, Espinosa-Ruiz JJ. Tiña capitis por *Microsporungypseum*, una especie infrecuente. *Archivos argentinos de pediatría*. 2018; 116(2):e296-9.
27. Segal E, Elad D. Human and zoonotic dermatophytoses: epidemiological aspects. *Frontiers in Microbiology*. 2021; 6;12:713532.
28. Gorbach SL, Bartlett JG, Blacklow NR, editors. *Infectious diseases*. Lippincott Williams & Wilkins; 2004.
29. Bhadauria S, Kumar P. Broad spectrum antidermatophytic drug for the control of tinea infection in human beings. *Mycoses*. 2012; 55(4):339-43.
30. Kanwar, AJ, Mamta CJ. Superficial fungal infections. In: Valia GR, editor. *IADVL Text book and Atlas of Dermatology*. 2nd ed. Mumbai: Bhalani Publishing House 2012; 215–58
31. Bhadauria S, Kumar S. Clinical manifestations of dermatophytoses a review. *Int. J. Sci. Res*. 2015; 4(1):428-31.
32. Achterman RR, Smith AR, Oliver BG, White TC. Sequenced dermatophyte strains: growth rate, conidiation, drug susceptibilities, and virulence in an invertebrate model. *Fungal genetics and biology*. 2011; 48(3):335-41.
33. Elewski BE. Tinea capitis: a current perspective. *Journal of the American Academy of Dermatology*. 2000; 42(1):1-20.

34. Bahaduria S, Jain N, Sharma M, Kumar P. Dermatophytoses in Jaipur: study of incidence, clinical features and causal agents. *Indian Journal of Microbiology*, 2001; 41(3), 207-210.
35. Ziegler W, Lempert S, Goebeler M, Kolb M, Mäurer A. Tinea capitis: temporal shift in pathogens and epidemiology. *JDDG: Journal der Deutschen Dermatologischen Gesellschaft*. 2016;14(8):818-25.
36. John AM, Schwartz RA, Janniger CK. The kerion: an angry tinea capitis. *International journal of dermatology*. 2018; 57(1):3-9.
37. Al Aboud AM, Crane JS. Tinea capitis. 2019; StatPearls.
38. Farooqi M, Tabassum S, Rizvi DA, Rahman A, Awan S, Mahar SA. Clinical types of tinea capitis and species identification in children: an experience from tertiary care centres of Karachi, Pakistan. *J Pak Med Assoc*. 2014; 64(3):304-8.
39. Leung AK, Hon KL, Leong KF, Barankin B, Lam JM. Tinea capitis: an updated review. *Recent Patents on Inflammation & Allergy Drug Discovery*. 2020;14(1):58-68.
40. Hsu S, Le EH, Khoshevis MR. Differential diagnosis of annular lesions. *American Family Physician*. 200; 64(2):289-97.
41. Surendran KA, Bhat RM, Bloor R, Nandakishore B, Sukumar D. A clinical and mycological study of dermatophytic infections. *Indian journal of dermatology*. 2014; 59(3):262-7.
42. Adams BB. Tinea corporis gladiatorum. *Journal of the American Academy of Dermatology*. 2002; 47(2):286-90.
43. Kelly BP. Superficial fungal infections. *Pediatrics in review*. 2012; 33(4):e22-37.
44. Hasegawa A. Dermatophytes from animals. *Nippon Ishinkin Gakkar Zasshi*. 2000; 41;1-4.
45. Rutecki GW, Wurtz R, Thomson RB. From animal to man: tinea barbae. *Current Infectious Disease Reports*. 2000; 2(5):433-7.
46. Romano C, Ghilardi A, Massai L. Eighty-four consecutive cases of tinea faciei in Siena, a retrospective study (1989–2003). *Mycoses*. 2005; 48(5):343-6.
47. Starova A, Stefanova, MB, Skerlev M. Tinea Faciei–Hypo Diagnosed Facial Dermatoses. *Maced J Med Sci*. 2010; 3(1), 27-31.
48. Zuber TJ, Baddam K. Superficial fungal infection of the skin: where and how it appears help determine therapy. *Postgraduate medicine*. 2001; 109(1):117-32.

49. Daniel III CR, Gupta AK, Daniel MP, Daniel CM. Two feet–one hand syndrome: a retrospective multicenter survey. *International journal of dermatology*. 1997; 36(9):658-60.
50. Zhan P, Geng C, Li Z, Jiang Q, Jin Y, Li C, Liu W. The epidemiology of tinea manuum in Nanchang area, South China. *Mycopathologia*. 2013 Aug;176(1):83-8.
51. Hainer BL. Dermatophyte infections. *American family physician*. 2003; 1;67(1):101-9.
52. Rezaei-Matehkolaei A, Makimura K, de Hoog S, Shidfar MR, Zaini F, Eshraghian M, Naghan PA, Mirhendi H. Molecular epidemiology of dermatophytosis in Tehran, Iran, a clinical and microbial survey. *Medical mycology*. 2013; 51(2):203-7.
53. Gupta AK, Chaudhry M, Elewski B. Tinea corporis, tinea cruris, tinea nigra, and piedra. *Dermatologic clinics*. 2003; 21(3):395-400.
54. Ely JW, Rosenfeld S, Stone MS. Diagnosis and management of tinea infections. *American family physician*. 2014; 90(10):702-11.
55. Moriarty B, Hay R, Morris-Jones R. The diagnosis and management of tinea. *Bmj*. 2012; 10;345.
56. Song G, Zhang M, Liu W, Liang G. Changing face of epidemiology of dermatophytoses in Chinese Mainland: A 30 years nationwide retrospective study from 1991 to 2020. *Mycoses*. 2022; 65(4):440-8.
57. Badiaga S, Menard A, Dupont HT, Ravoux I, Chouquet D, Graveriau C, Raoult D, Brouqui P. Prevalence of skin infections in sheltered homeless of Marseilles (France). *European journal of dermatology*. 2005; 15(5):382-6.
58. Nowicka D, Nawrot U. Tinea pedis—An embarrassing problem for health and beauty—A narrative review. *Mycoses*. 2021; 64(10):1140-50.
59. MELİKOĞLU M, ÖZDEMİR Ş, Uslu H. The investigation of dermatophyte agents in patients with dermatophytosis diagnosis. *Medicine Science*. 2023;12(1).
60. To MJ, Brothers TD, Van Zoost C. Foot conditions among homeless persons: a systematic review. *PLoS One*. 2016; 11(12):e0167463.
61. Stratigos AJ, Stern R, González E, Johnson RA, O'Connell J, Dover JS. Prevalence of skin disease in a cohort of shelter-based homeless men. *Journal of the American Academy of Dermatology*. 1999; 41(2):197-202.
62. Mazza M, Refojo N, Davel G, Lima N, Dias N, da Silva CM, Canteros CE. Epidemiology of dermatophytoses in 31 municipalities of the province of Buenos

- Aires, Argentina: a 6-year study. *Revista Iberoamericana de Micología*. 2018; 35(2):97-102.
63. Nakamura K, Fukuda T. 2021 Epidemiological survey of dermatomycoses in Japan. *Medical mycology journal*. 2023; 31;64(4):85-94.
 64. Perea S, Ramos MJ, Garau M, Gonzalez A, Noriega AR, del Palacio A. Prevalence and risk factors of tinea unguium and tinea pedis in the general population in Spain. *Journal of clinical microbiology*. 2000; 38(9):3226-30.
 65. Lipner SR, Scher RK. Onychomycosis: Clinical overview and diagnosis. *Journal of the American Academy of Dermatology*. 2019; 80(4):835-51.
 66. Gupta AK, Stec N, Summerbell RC, Shear NH, Piguat V, Tosti A, Piraccini BM. Onychomycosis: a review. *Journal of the European Academy of Dermatology and Venereology*. 2020; 34(9):1972-90.
 67. Bologna JL, Schaffer JV, Cerroni L. *Dermatology*. Elsevier: Amsterdam, The Netherlands. 2017; ISBN 978-0-7020-6275-9.
 68. Sahni K, Singh S, Dogra S. Newer topical treatments in skin and nail dermatophyte infections. *Indian dermatology online journal*. 2018; 9(3):149-58.
 69. Hay R. Therapy of skin, hair and nail fungal infections. *Journal of Fungi*. 2018; 20;4(3):99.
 70. McKeny PT, Nessel TA, Zito PM. Antifungal antibiotics. In *StatPearls*. StatPearls Publishing. 2022; PMID: 30844195.
 71. Sahni T, Sharma S, Arora G, Verma D. Synthesis, characterization and antifungal activity of a substituted coumarin and its derivatives. *Pesticide Research Journal*. 2020; 32(1):39-48.
 72. Zhang AY, Camp WL, Elewski BE. Advances in topical and systemic antifungals. *Dermatologic clinics*. 2007; 25(2):165-83.
 73. Gupta AK, Foley KA, Versteeg SG. New antifungal agents and new formulations against dermatophytes. *Mycopathologia*. 2017; 182(1):127-41.
 74. Asz-Sigall D, Tosti A, Arenas R. Tinea unguium: diagnosis and treatment in practice. *Mycopathologia*. 2017; 182:95-100.
 75. Ugalde-Trejo NX, Delgado Moreno KP, Alfaro-Sánchez A, Tirado-Sánchez A, Bonifaz Trujillo JA. Two feet-one hand syndrome: tinea pedis and tinea manuum. *Current Fungal Infection Reports*. 2022; 16(4):117-25.
 76. Nenoff P, Schetschorke C. Tinea Faciei. *N Engl J Med*. 2014; 370(20), 31.

77. Fuller LC, Barton RC, Mohd Mustapa MF, Proudfoot LE, Punjabi SP, Higgins EM, Hughes JR, Sahota A, Griffiths M, McDonagh AJ, Punjabi S. British Association of Dermatologists' guidelines for the management of tinea capitis 2014. *British Journal of Dermatology*. 2014; 171(3):454-63.
78. Hoffman LK, Raymond I, Kircik L. Treatment of Signs and Symptoms (Pruritus) of Interdigital Tinea Pedis With Econazole Nitrate Foam, 1. *Journal of Drugs in Dermatology: JDD*. 2018 Feb 1;17(2):229-32.
79. Choudhary SV, Bisati S, Singh AL, Koley S. Efficacy and safety of terbinafine hydrochloride 1% cream vs. sertaconazole nitrate 2% cream in tinea corporis and tinea cruris: a comparative therapeutic trial. *Indian journal of Dermatology*. 2013; 58(6):457-60.
80. Shivamurthy RP, Reddy SG, Kallappa R, Somashekar SA, Patil D, Patil UN. Comparison of topical anti-fungal agents sertaconazole and clotrimazole in the treatment of tinea corporis-an observational study. *Journal of Clinical and Diagnostic Research: JCDR*. 2014; 8(9):HC09.
81. Banerjee M, Ghosh AK, Basak S, Das KD, Gangopadhyay DN. Comparative evaluation of effectivity and safety of topical amorolfine and clotrimazole in the treatment of tinea corporis. *Indian journal of dermatology*. 2011; 56(6):657-62.
82. Glynn M, Jo W, Minowa K, Sanada H, Nejishima H, Matsuuchi H, Okamura H, Pillai R, Mutter L. Efinaconazole: Developmental and reproductive toxicity potential of a novel antifungal azole. *Reproductive Toxicology*. 2015; 52:18-25.
83. Gupta AK, Cooper EA. Long-term Efficacy and Safety of Once-daily Efinaconazole 10% Topical Solution (Jublia) for Dermatophyte Toenail Onychomycosis: An Interim Analysis. *Skin Therapy Letter*. 2021; 26(1):5-10.
84. Kamarthi M, Raghav MV, Kamath L, Revathi TN. Study to Evaluate the Efficacy and Safety of Topical Lipid-based Amphotericin B Gel 0.1% in Patients with Cutaneous Mycosis Resistant to Conventional Therapy. *Pharmacology and Clinical Pharmacy Research*. 2022; 7(3):134-41.
85. Parish LC, Parish JL, Routh HB, Avakian E, Olayinka B, Pappert EJ, Plaum S, Fleischer AB, Hardas B. A double-blind, randomized, vehicle-controlled study evaluating the efficacy and safety of naftifine 2% cream in tinea cruris. *Journal of Drugs in Dermatology: JDD*. 2011; 10(10):1142-7.
86. Khanna D, Bharti S. Luliconazole for the treatment of fungal infections: an evidence-based review. *Core evidence*. 2014; 113-24.

87. Gnat S, Łagowski D, Nowakiewicz A. Major challenges and perspectives in the diagnostics and treatment of dermatophyte infections. *Journal of applied microbiology*. 2020;129(2):212-32.
88. Zuzarte M, Gonçalves MJ, Canhoto J, Salgueiro L. Antidermatophytic activity of essential oils. *Science against microbial pathogens: communicating current research and technological advances*. 2011; 1167-78.

UNDER PEER REVIEW